Picton Mahoney Asset Management Sells 2,439 Shares of Natera, Inc. (NASDAQ:NTRA)

Picton Mahoney Asset Management trimmed its holdings in Natera, Inc. (NASDAQ:NTRA) by 2.5% in the 4th quarter, Holdings Channel reports. The fund owned 95,390 shares of the medical research company’s stock after selling 2,439 shares during the quarter. Picton Mahoney Asset Management’s holdings in Natera were worth $15,100,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of NTRA. Assetmark Inc. boosted its position in shares of Natera by 2.1% in the third quarter. Assetmark Inc. now owns 7,353 shares of the medical research company’s stock valued at $933,000 after acquiring an additional 150 shares during the period. Covestor Ltd lifted its position in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Apollon Wealth Management LLC bought a new position in Natera in the third quarter worth $270,000. Sumitomo Mitsui Trust Group Inc. lifted its position in Natera by 29.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 671,382 shares of the medical research company’s stock worth $85,232,000 after purchasing an additional 153,441 shares during the period. Finally, Victory Capital Management Inc. lifted its position in Natera by 4.2% in the third quarter. Victory Capital Management Inc. now owns 315,543 shares of the medical research company’s stock worth $40,058,000 after purchasing an additional 12,815 shares during the period. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on NTRA shares. Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. The Goldman Sachs Group raised their target price on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Finally, Morgan Stanley lifted their price objective on Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $178.12.

Insider Buying and Selling

In related news, insider John Fesko sold 663 shares of Natera stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 43,502 shares of Natera stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $176.88, for a total value of $7,694,633.76. Following the completion of the sale, the chief financial officer now owns 70,629 shares of the company’s stock, valued at approximately $12,492,857.52. The trade was a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 298,946 shares of company stock worth $47,803,462 over the last three months. 7.60% of the stock is currently owned by company insiders.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $148.22 on Friday. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The firm has a market cap of $20.04 billion, a PE ratio of -84.22 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The business has a fifty day moving average of $164.09 and a 200-day moving average of $148.21.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.